Home › Why I'm Not Giving Up on This Tiny Biotech Stock
 

Keywords :   


Why I'm Not Giving Up on This Tiny Biotech Stock

2015-03-18 15:22:51| Biotech - Topix.net

Since reporting in November that its promising hepatitis C drug ACH-3102 helped clear the virus from 100% of patients in a small clinical trial, shares in Achillion Pharmaceuticals Sovaldi last year revolutionized hepatitis C treatment. Sovaldi cast aside reliance on side-affect-laden peginterferon and cut patient treatment times in half, to 12 weeks, all while delivering functional cure rates of 90% or more.

Tags: stock giving tiny biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Ansell Completes Acquisition of Kimberly-Clarks PPE Business
02.07Ecolab Launches 100% Plastic-Free Wipe for Healthcare Settings
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Chattanooga Area High School Students Graduate from BASFs TECH Academy
02.07Atlantic Tropical Weather Outlook
02.07Fayette Pipe Transforms Black Steel Pipe with FayetteGuard
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 16A
More »